Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells
Open Access
- 9 July 2021
- journal article
- research article
- Published by Elsevier in Neurotherapeutics
- Vol. 18 (3) , 1783-1797
Abstract
No abstract availableKeywords
Funding Information
- Novartis Pharma (CFTY720DDE08T)
- Charité - Universitätsmedizin Berlin
This publication has 105 references indexed in Scilit:
- Organ-specific features of natural killer cellsNature Reviews Immunology, 2011
- Analyses of phenotypic and functional characteristics of CX3CR1‐expressing natural killer cellsImmunology, 2011
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple SclerosisClinical Neuropharmacology, 2010
- T-bet–dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrowJournal of Experimental Medicine, 2009
- Activation of Natural Killer Cells by Newcastle Disease Virus Hemagglutinin-NeuraminidaseJournal of Virology, 2009
- Autoimmune T cell responses in the central nervous systemNature Reviews Immunology, 2009
- Sphingosine-1-phosphate and modulation of vascular toneCardiovascular Research, 2009
- Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cellsClinical and Experimental Immunology, 2007
- Regulatory CD56brightnatural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosisProceedings of the National Academy of Sciences, 2006